(Q44397618)

2 December 2017

title

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome (English)

1 reference

2 December 2017

1 reference

1 reference

1 reference

1 reference

7

Scott M Grundy

1 reference

2 December 2017

1

Gloria Lena Vega

1 reference

2 December 2017

Patrick T S Ma

2

1 reference

2 December 2017

Nilo B Cater

3

1 reference

2 December 2017

Neil Filipchuk

4

1 reference

2 December 2017

Shinichi Meguro

5

1 reference

2 December 2017

Ana Barbara Garcia-Garcia

6

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

American Journal of Cardiology

2 December 2017

published in

1 reference

2 December 2017

volume

91

1 reference

2 December 2017

issue

8

1 reference

2 December 2017

page(s)

956-960

1 reference

Combination drug therapy for familial combined hyperlipidemia

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Statin-fibrate combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Myopathy due to statin/fibrate use in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Cerivastatin and reports of fatal rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Mechanistic studies on metabolic interactions between gemfibrozil and statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900111-5

10.1016/S0002-9149(03)00111-5

7 January 2021

Identifiers

DOI

1 reference

2 December 2017

1 reference